Research programme: beta-1,3-D-glucan synthase inhibitors - Merck/SCYNEXIS

Drug Profile

Research programme: beta-1,3-D-glucan synthase inhibitors - Merck/SCYNEXIS

Alternative Names: Antifungals - Merck/SCYNEXIS; Enfumafungin derivatives - Merck/SCYNEXIS

Latest Information Update: 26 Aug 2011

Price : $50

At a glance

  • Originator Merck & Co; SCYNEXIS
  • Class Echinocandins; Glycosides; Triterpenes
  • Mechanism of Action Beta-1,3-D glucan synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Mycoses
  • Discontinued Bacterial infections

Most Recent Events

  • 15 Sep 2009 Pharmacodynamics and Antimicrobial data from a preclinical trial in mycosis presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009) ,,
  • 05 Oct 2006 No development reported - Preclinical for Bacterial infections in USA (unspecified route)
  • 18 Jul 2003 SCYNEXIS and Merck have extended this research collaboration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top